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Introduction: Venous thrombosis (VT) and inflammation are two closely related
entities. In the present investigation we assessed whether there is a relation between
genetic modifiers of the inflammatory response and the risk of VT.
Materials and methods: 420 consecutive and unrelated patients with an objective
diagnosis of deep VTand 420 matched controls were investigated. The frequencies of
the following gene polymorphisms were determined in all subjects: TNF-α−308 G/A,
LT-α+252 A/G, IL-6-174 G/C, IL1-ra 86 bp VNTR, IL-10-1082 A/G and CD-31 125 C/G.
Results: Overall odds ratio (OR) for VTrelated to TNF-α−308 G/A, LT-α+252 A/G, IL-6-
174 G/C, A1 allele (4 bp repeat) of the IL1-ra 86 bp VNTR, IL-10-1082 A/G and CD-31
125 C/G were respectively: 1.0 (CI95: 0.8–1.5), 1.3 (CI95: 1.0–1.7), 1.1 (CI95: 0.9–
1.5), 1.6 (CI95: 1–2.5), 1.2 (CI95: 0.8–1.7) and 0.8 (CI95: 0.6–1.1). A possible
interaction between polymorphisms was observed only for the co-inheritance of the
mutant alleles of the LT-α+252 A/G and IL-10-1082 G/A polymorphisms (OR=2; CI95:
1.1–3.8). The risk of VT conferred by factor V Leiden and FII G20210A was not
substantially altered by co-inheritance with any of the cytokine gene polymorphisms.
Conclusions: Cytokine gene polymorphisms here investigated did not significantly
influence venous thrombotic risk.
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Venous thrombosis is a prevalent disease that is





trait, because several genetic and environmental
factors contribute to its occurrence [1,2]. A list of
well-established genetic risk factors of VT is now
known; the main genetic abnormalities associated
with increased risk of VT are the inherited defi-
ciencies of antithrombin, protein C and protein S,
and the point mutations known as factor V Leiden
(FVL) and factor II (FII) G20210A. The association
of other specific gene defects with thrombotic risk
is less well-established or controversial.
Inflammation and VT are two closely related
entities and the inflammatory process is associat-
ed with thrombogenesis through different
mechanisms. One mechanism is the induction of
pro-coagulant factors: tumor necrosis factor-alpha
(TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6)
and interleukin-8 (IL-8) have the potential to elicit
tissue factor (TF) expression on endothelial cells
and monocytes in vitro [3–5] and in vivo [6–10].
Another mechanism linking inflammation to
thrombosis is inhibition of natural anticoagulants:
TNF-α and IL-1 can induce internalization of
thrombomodulin [11], inhibit transcription of the
thrombomodulin gene [12] and inhibit the action
of the heparin–antithrombin complex through
glucosaminoglicans (GAGs) reduction on the vas-
cular endothelial surface [13]. TNF-α can also
inhibit fibrinolysis by increasing plasma levels of
plasminogen activator inhibitor-1 (PAI-1) and PAI-2
[14], and IL-6 secretion is associated with platelet
production [15]. Other lines of evidence linking
inflammation to VT derive from animal studies
dealing with the role of TNF-α, IL-6 and interleu-
kin-10 (IL-10, an anti-inflammatory cytokine) in
influencing the regulation of the inflammation
process and thrombus formation [16,17], and from
clinical, case-control studies in humans, such as
the LETS (Leiden Thrombophilia Study), which has
shown a mild but significant increase in risk to VT
associated with high levels of TNF-α, IL-1β, IL-6
and IL-8 [18].
Given the above-mentioned data, it is conceiv-
able that cytokines with known polymorphic gene
sequences are potential risk factors for venous
thrombotic disease insofar as the gene products
seem to be involved in VT pathogenesis [19]. Several
polymorphisms in cytokine-coding genes have been
described and some of them will be briefly pre-
sented here. AG to A transition at nucleotide−308 in
the TNF-α gene promoter (designated TNF2 allele)
[20] is a stronger transcription activator than the
common TNF1 allele [21,22] and is therefore acandidate risk factor for multifactorial diseases in
which inflammation plays a role. Also of interest is a
−252 A to G transition in the first intron of the
lymphotoxin-alpha (LT-α) gene [23]; LT-α stimulates
adhesion molecule production, thrombogenesis,
smooth muscle proliferation, platelet activation
and release of vasoactive agents [22], and the
mutant (G) allele results in higher gene transcription
and increased LT-α by in vitro stimulated mononu-
clear cells [22]. Other candidate risk factors for
thrombosis (because of their relation with inflam-
mation) are: a G to C transition at nucleotide −174 in
the IL-6 gene (the G allele is a stronger transcription
activator than the common C allele and is associated
with higher plasma levels of IL-6) [24]; an 86-bp
VNTR in intron 2 of the IL-1ra gene (that determines
five alleles corresponding to 2, 3, 4, 5 and 6 copies of
the 86 bp sequence) [25] — the number of repeats
may influence gene transcription and protein pro-
duction, and carriership of the A1 allele has been
shown to be associated with higher IL-1ra secretion
by mononuclear cells) [26]; a G to A transition at
nucleotide −1082 in the promoter region of IL-10
gene (the A allele is correlated with lower produc-
tion of IL-10 in Tcells stimulated in vitro) [27]; a C to
G substitution at codon 125 of platelet-endothelial-
cell adhesion molecule 1 (PECAM-1, or CD-31) gene
that is associated with a higher risk to GVHD in bone
marrow transplantation [28]. CD-31 is a membrane
glycoprotein that is constitutively expressed on
vascular endothelial cells, platelets, most circulat-
ing leukocytes and bone marrow stem cells [29], and
it is believed to have a role in interactions between
leukocytes and endothelial cells, attracting leuko-
cytes to inflammatory sites and possibly influencing
angiogenesis [30].
Thus, the information available on the role of
inflammatory mediators in VT encouraged us to con-
duct this investigation, in order to test the hypothesis
that polymorphisms in the TNF-α, LT-α, IL-6, IL-1ra,
IL-10 and CD-31 genes might be related to increased
risk of VT. Each cytokine gene polymorphism was
selected either because other studies suggested that
it may influence the predisposition or outcome of
multifactorial diseases, or because the variant was
demonstrated to result in functional changes or
altered expression of cytokines.
Subjects and methods
Patients and controls
The description of the BRATROS was published pre-
viously [31,32]. Included were four hundred thirty-
four patients, consecutively admitted between
October 1996 and August 2001, with an objectively
Table 1 BRATROS: general characteristics of patients





Median age (range) 42 (2–70) 42 (2–70)
Male/Female ratio 0.7 0.7
Ethnicity
Whites 84.3% 84.3%
Blacks and Mulattos 15.6% 15.6%
Asians 0.1% 0.1%
Family history of VT 22% –#
Spontaneous VT 53.4% –#
Acquired risk factors for VT⁎ 46.6% –#
Genetic factors for VT
Factor V Leiden 10.5% 2.4%
Factor II G20210A 6.6% 1.2%
Inherited inhibitor deficiency & 9.5% –#
⁎Surgery/trauma/immobilisation, pregnancy/puerperium, and
hormone use.
&Antithrombin, protein C and protein S deficiencies taken
together.
#Information not available for all subjects.
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with lower limb VT, 23 patients with upper limb VT, 4
patients with intra-abdominal thrombosis, 40 with
central VT, and 7 with thrombosis in other sites.
Nine patients had VT in more than one site). Sub-
jects aged more than 70 years or with malignant
disease were excluded. Cases enrolled came fromTable 2 Summary of methodological information on detec
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Denaturation 94°C, 1 min 94°C, 1 min 94°C, 40 se
Annealing 60°C, 1 min 65°C, 1 min 59°C, 58 se
Extension 72°C, 1 min 72°C, 2 min 72°C, 1 mi




Allele (bp) −308G: 20+87 +252A: 368 −174G: 119
−308A: 107 +252G: 235+133 −174C: 70+three Brazilian University Hospitals: School of Medi-
cine of Ribeirão Preto (University of São Paulo, USP),
School of Medicine of Botucatu (State University of
São Paulo, UNESP) and Federal University of São
Paulo (UNIFESP). Data on exposure to acquired risk
factors for VT, i.e. immobilisation, surgery, trauma,
use of oral contraceptives and hormone replacement
therapy, were collected. Four hundred thirty-four
controls (unrelated healthy blood donor candidates
without a personal history of thrombosis) werematch-
ed with the patients for gender, age (±4 years), race,
and time of recruitment. For the purposes of the
present investigation, samples from 420 patients (out
of the 434 cases originally included), and from the 420
respective controls, were available to be analysed.
Table 1 lists general characteristics of the patient
study group. The Institutional Ethical Committee
approved this study and informed consent was
obtained from the participants.
Mutation analysis
With the use of public databases, we selected cyto-
kine gene polymorphisms that were suggested to
influence predisposition and/or outcome of multi-
factorial diseases, or that were demonstrated to
result in functional changes or altered expression of
cytokines. Peripheral blood was collected and
genomic DNA extracted from mononuclear leuko-
cytes by the salting-out method [33]. Genotypingtion of cytokine gene polymorphisms investigated
IL-1ra IL-10 CD-31
86-bp VNTR G/A C/G
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I: 410 IV: 325 −1082G:134+
33+25+23+12
−125C: 237+78+49
49 II: 240 V: 595 −1082A:134+
33+48+12
−125G: 315+49
III: 500 VI: 120
224 F. Pieroni et al.for each gene variation was performed by employing
PCR and restriction–digestion protocols published
previously [20,24,25,27,28], whose main character-
istics are summarized in Table 2.Statistical analysisTable 3 Prevalence of TNF-α −308 G/A, LT-α +252
A/G, IL-1ra 86 bp VNTR, IL-6-174G/C, IL-10-1082G/A








GG 318 (76%) 312 (74%) 1a
GA 92 (22%) 101 (24%) 1.1 (0.8–1.5)Allele frequencies were calculated by gene counting
fromobserved genotypes. Odds ratios (OR)were calc-
ulated as an estimate of the relative risk of VT in an
exposed category of subjects in relation to a re-
ference category for which the OR is arbitrarily 1.0.
95% confidence intervals (CI95) were calculated by
standard methods [34]. To search for interaction
between cytokine gene polymorphisms and between
these gene variations and prothrombotic mutations
(FVL and FII G20210A), stratified analyses were per-
formed. Thus, interaction between the cytokine
polymorphisms was searched for by performing two-
by-two stratified analyses, due to the rarity of co-
inheritance of more than two polymorphisms (which
would yield OR with too wide confidence intervals).
By testing the combination of the six gene variations
two by two, 15 different scenarios of co-inheritance
were eventually analysed to look for gene–gene in-
teractions. When testing these scenarios, the geno-
types were combined according to their expected
pro-inflammatory effect.AA 10 (2%) 7 (2%) 0.7 (0.2–1.9)
GA+AA 102 (24%) 108 (26%) 1 (0.8–1.5)
LT-α+252 A/G
AA 198 (47%) 170 (40%) 1a
AG 179 (43%) 203 (48%) 1.3 (1.0–1.7)
GG 43 (10%) 47 (11%) 1.3 (0.8–2)
AG+GG 222 (53%) 250 (60%) 1.3 (1–1.7)
IL-6 -174 G/C
GG 232 (55%) 217 (52%) 1a
GC 153 (36%) 172 (41%) 1.2 (0.9–1.6)
CC 35 (9%) 31 (7%) 0.9 (0.5–1.6)
GC+CC 188 (45%) 203 (48%) 1.1 (0.9–1.5)
IL-1ra 86 bp VNTR
Allele A1 (−) 46 (11%) 30 (7%) 1a
Allele A1 (+) 374 (89%) 390 (93%) 1.6 (1–2.5)
IL-10 -1082 G/A
GG 66 (16%) 57 (13%) 1a
GA 176 (42%) 201 (48%) 1.3 (0.9–2)
AA 178 (42%) 162 (39%) 1 (0.7–1.6)
GA+AA 354 (84%) 363 (86%) 1.2 (0.8–1.7)
CD-31 125C/G
CC 95 (23%) 109 (26%) 1a
CG 212 (50%) 205 (49%) 0.8 (0.6–1.2)
GG 113 (27%) 106 (25%) 0.8 (0.5–1.1)
CG+GG 325 (77%) 311 (74%) 0.8 (0.6–1.1)
a Reference category.Results
TNF-α-308 G/A, LT-α+252 A/G, IL-6-174G/C,
VNTR IL-1ra, IL-10-1082G/A andCD-31125C/G
polymorphisms and the risk of VT
The mutant TNF-α allele was found in 102/420
controls (allele frequency 13%, carrier frequency
24%) and in 108/420 patients with VT (allele fre-
quency 14%, carrier frequency 26%). These data
yielded an overall OR for VT related to the TNF-α
polymorphism of 1 (CI95: 0.8–1.5). The OR for homo-
zygotes was 0.7 (CI95: 0.2–1.9), and for heterozy-
gotes theORwas 1.1 (CI95: 0.8–1.5). Themutant LT-α
allele was found in 222/420 controls (allele frequency
32%, carrier frequency 53%) and in 250/420 patients
with VT (allele frequency 35%, carrier frequency
60%). These data yielded an overall OR for VTrelated
to the LT-α polymorphism of 1.3 (CI95: 1–1.7). The OR
for homozygotes was 1.3 (CI95: 0.8–2), and for
heterozygotes the OR was 1.3 (CI95: 1–1.7) (Table 3).
The mutant (C) IL-6 allele was found in 188/420
controls (allele frequency 27%, carrier frequency
45%) and in 203/420 patients with VT (allele
frequency 28%, carrier frequency 48%), yielding anoverall OR for VT of 1.1 (CI95: 0.9–1.5). The OR for
homozygotes was 0.9 (CI95: 0.5–1.6), and for
heterozygotes the OR was 1.2 (CI95: 0.9–1.6).
The A1 allele of the VNTR IL-1ra was found in
374/420 controls (allele frequency 71%, carrier fre-
quency 89%) and in 390/420 patients (allele fre-
quency 72.5%, carrier frequency 93%). Overall OR
for VTrelated to the A1 allele was 1.6 (CI95: 1–2.5).
The mutant IL-10 allele was found in 354/420
controls (allele frequency 64%, carrier frequency
84%) and in 363/420 patients with VT (allele fre-
quency 62%, carrier frequency 86%). These data
yielded an overall OR for VT related to the IL-10
polymorphism of 1.2 (CI95: 0.8–1.7). The OR for
homozygotes was 1 (CI95: 0.7–1.6), and for hetero-
zygotes the OR was 1.3 (CI95: 0.9–2).
The mutant CD-31 allele was found in 325 out of
420 controls (allele frequency 52%, carrier frequency
77%) and in 311 out 420 patients with VT (allele
frequency 49%, carrier frequency 74%). These data
Table 4 TNF-α−308 G/A, LT-α+252 A/G, IL-6-174G/C, IL-1ra 86bp VNTR, IL-10-1082G/A and CD-31 125 C/G
polymorphisms: combined inheritance and thrombotic risk
a Reference category.
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polymorphismof 0.8 (CI95: 0.6–1.1) (Table 3). TheOR
for homozygotes was 0.8 (CI95: 0.5–1.1), and for
heterozygotes the OR was 0.8 (CI95: 0.6–1.2).
Interaction between TNF-α−308 G/A,
LT-α+252 A/G, IL-6-174G/C, IL-1ra 86
bp VNTR, IL-10-1082G/A and CD-31 125 C/G
The frequencies of the co-inherited genotypes, and
the correspondent OR and the CI95, are shown inTable 4. Significant interaction between polymorph-
isms was observed only for the co-inheritance of the
mutant alleles (AG+ GG genotypes) of the LT-α+252
A/G polymorphism and the GA+ AA genotypes of the
IL-10-1082 G/A polymorphism. The wild LT-α geno-
type co-inherited with the wild IL-10 alleles was
found in 34/420 controls (carrier frequency 8%) and in
18/420 patients with VT (carrier frequency 4%), and
the co-inheritance of the mutant LT-α with the
mutant IL-10 alleles was found in 191/420 controls
(carrier frequency 45%) and in 211/420 patients with
VT (carrier frequency 50%). These data yielded an
Table 5 TNF-α−308 G/A, LT-α+252 A/G, IL-6-174G/C, IL-1ra 86bp VNTR, IL-10-1082G/A, CD-31 125 C/G: co-inheritance
with FV Leiden and thrombotic risk
a Reference category.
226 F. Pieroni et al.overall OR for VT of 2 (CI95: 1.1–3.8) related to the
wild LT-α plus wild IL-10 alleles (Table 4).
Interaction between cytokine gene
polymorphisms, factor V Leiden and factor II
G20210A
We also examined the possibility that each cytokine
gene polymorphism tested in this study might
interact with FVL and FII G20210A. The overall OR
for VT associated with FVL was 4.7 (CI95: 2.3–9.4),
and for FII G20210A the OR was 7.1 (CI95: 2.5–20.6)
(prevalence of both mutations in patients and
controls are shown in Table 1). Similar frequenciesTable 6 TNF-α−308 G/A, LT-α+252 A/G, IL-6-174G/C, IL-1ra 86bp VN
with FII G20210A and thrombotic risk
a Reference category.of all studied polymorphisms were found in patients
and controls carrying or not carrying FVL or FII
G20210A. The OR and respective CI95 calculated for
each scenario of co-inheritance of FVL/FII G20210A
with a given cytokine gene variant show an overlap
with the OR and CI95 for FVL and FII G20210A,
indicating that neither of the two prothrombotic
mutations interacts with the cytokine polymorph-
isms investigated (Tables 5 and 6).
Discussion
We tested the hypothesis that specific polymorphisms
in cytokine genes are risk factors for VT. Additionally,TR, IL-10-1082G/A, CD-31 125 C/G: co-inheritance
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polymorphisms and between these gene variants and
the prothrombotic mutations FVL and FII G20210A.
The prevalence of TNF-α−308 G/A, LT-α+252 A/G,
IL-6-174 G/C, IL-1ra 86 bp VNTR, IL-10-1082G/A and
CD-31 125 C/G polymorphisms did not differ signif-
icantly between patients with VT and controls,
isolated or combined two by two. One exception
might be the co-inheritance of mutant alleles for LT-
α+252 A/G and IL-10-1082 G/A, which was found to
be associated with a two-fold increase in thrombotic
risk. However, this finding requires confirmation. The
risk of VT conferred by FVL and FII G20210A was not
substantially altered by co-inheritance with any of
the cytokine gene polymorphisms tested.
A previous study has examined the TNF α 308 G/A
polymorphism as a candidate risk factor for VT [35].
The work enrolled 575 patients with VT and 511
controls, and did not detect a significant risk for VT
in relation to TNF α 308 G/A polymorphism, isolated
or in combination with FVL. Our findings agree with
those results, and taken together the data from
both studies do not point to a relevant role of this
gene variation as risk factor in VT.
In spite of several evidences from literature
pointing to a link between in vitro levels of TNF α, IL
1 and IL 6 and hypercoagulability [3–5,11–15], and
between plasma levels of TNFα and IL 6 and increased
thrombotic risk in animals [36] and humans [6,8–
10,18], the negative findings from the present in-
vestigation may lead us to speculate that increased
cytokine secretion generated by isolated mutants
alleles is insufficient to trigger a prothrombotic state
with clinical repercussion. In agreement with such
possibility are the findings of a work showing that
administration of maximal doses of TNF α to humans
does not cause VT [37].
The literature associates less intensity of throm-
bosis, in murine models, with high levels of IL 10
[16,38,39], and other data suggest a tendency to a
lower risk of VT in patients with high plasma levels of
this cytokine [18]. Here again, wemight suggest that
the lower levels of IL 10, associated with carriership
of the A allele of the IL 10-1082 G/A polymorphism,
are not sufficient to trigger VT. Still with regards to
the IL-10 polymorphism, it should bementioned that
the evidence for an association between low IL-10
levels and VT derive mainly from animal studies, so
that it cannot be ruled out that the absence of a
thrombotic risk associated to the A allele in the
incidence of VT is due to a variable response of the
cytokine in relation to the species studied. Such a
possibility was also reported for TNF-α [40].
The LT-α+252A/G polymorphism was charac-
terised as a risk factor for myocardial infarction
(MI) in two studies [41,42] and the CD-31 125C/Gwas found to be a risk factor for GVHD in bone
marrow transplantation in humans [28] and also risk
factor for MI [43]. Despite these data suggesting a
participation of these polymorphisms in the risk of
diseases in which inflammation plays a role, these
variants did not influence the risk of venous throm-
botic disease in the present study.
With regards to the two-fold increase in venous
thrombotic risk associated to the co-inheritance of
the LT-α+252 A/G and IL-10-1082G/A, it may be
suggested that the existence of a pro-inflammatory
state in this scenario gives rise to a higher production
of LT-α and low production of IL-10, and this specific
combination may be capable of inducing a pro-
coagulant state and of triggering VT. However, there
is a clear need for additional studies to explore such
a hypothesis as well as to confirm the suggestion of
the association yielded by our investigation.
To sum, despite evidences that VTand inflamma-
tion are two closely related entities, and that
several cytokine gene polymorphisms influence
cytokine production and may be causally related to
some complex traits, the results from our investiga-
tion indicate that (either isolated or combined) the
cytokine genetic variations here investigated are
unlikely to contribute to the risk of VT.
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